Statements (17)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:activeIngredient |
gptkb:omega-3-carboxylic_acids
|
| gptkbp:ATCCode |
gptkb:C10AX14
|
| gptkbp:contains |
gptkb:eicosapentaenoic_acid
docosahexaenoic acid |
| gptkbp:form |
soft gelatin capsule
|
| https://www.w3.org/2000/01/rdf-schema#label |
Epanova
|
| gptkbp:indication |
severe hypertriglyceridemia
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:AstraZeneca
|
| gptkbp:marketWithdrawalReason |
lack of efficacy in cardiovascular outcomes trial
|
| gptkbp:regulates |
approved (2014)
withdrawn (2020) |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:usedFor |
hypertriglyceridemia
|
| gptkbp:bfsParent |
gptkb:AstraZeneca_US
|
| gptkbp:bfsLayer |
6
|